Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 22, Issue 4

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Expert Opinion on Investigational Drugs, Volume 22, Issue 4 (2013)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 22, Issue 4 (2013)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Volume 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Agomelatine, melatonin and depressive disorder

Trevor R Norman

Pages: 407-410

Published online: 13 Mar 2013

AbstractforAgomelatine, melatonin and depressive disorder | Full Text | References | PDF (163.7 KB)

3202 Views
3 CrossRef citations
0Altmetric

Free Access

Reviews

Review Article

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders

Tiago A Mestre MD MSc, Mateusz Zurowski FRCP & Susan H Fox MRCP PhD

Pages: 411-421

Published online: 15 Feb 2013

Abstractfor5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders | Full Text | References | PDF (236.1 KB)

1082 Views
46 CrossRef citations
0Altmetric

Review Article

Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation

Peter SE Davies MBChB, Simon M Graham MBChB MRCS, Robert J MacFarlane MBChB MRCS, Andreas Leonidou MBChB MRCS, Athanasios Mantalaris BSc PhD & Eleftherios Tsiridis MD MSc PhD FRCS

Pages: 423-441

Published online: 14 Feb 2013

AbstractforDisease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation | Full Text | References | PDF (263.4 KB)

862 Views
26 CrossRef citations
0Altmetric

Review Article

Optimizing biologically targeted clinical trials for neurofibromatosis

David H Gutmann MD PhD, Jaishri O Blakeley MD, Bruce R Korf MD PhD & Roger J Packer MD

Pages: 443-462

Published online: 21 Feb 2013

AbstractforOptimizing biologically targeted clinical trials for neurofibromatosis | Full Text | References | PDF (883.5 KB)

482 Views
68 CrossRef citations
0Altmetric

Review Article

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus

William N Washburn & Simon M Poucher BSc (Hons) PhD FBPharmacolS

Pages: 463-486

Published online: 01 Mar 2013

AbstractforDifferentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus | Full Text | References | PDF (545.2 KB)

2475 Views
65 CrossRef citations
0Altmetric

Review Article

Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?

Lauren M Cornall, Michael L Mathai, Deanne H Hryciw & Andrew J McAinch

Pages: 487-498

Published online: 27 Feb 2013

AbstractforIs GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? | Full Text | References | PDF (506.4 KB)

661 Views
17 CrossRef citations
0Altmetric

Review Article

Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis

Sushmita Chakraborty PhD, Puneet Chopra PhD, Anushree Hak B Tech, Sunanda Ghosh Dastidar PhD & Abhijit Ray PhD

Pages: 499-515

Published online: 13 Mar 2013

AbstractforHepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis | Full Text | References | PDF (756.3 KB)

590 Views
42 CrossRef citations
0Altmetric

Review Article

Opioid antagonists for pain

Robert Taylor Jr PhD, Joseph V Pergolizzi Jr MD, Frank Porreca PhD & Robert B Raffa PhD

Pages: 517-525

Published online: 13 Mar 2013

AbstractforOpioid antagonists for pain | Full Text | References | PDF (314.5 KB)

573 Views
11 CrossRef citations
0Altmetric

Drug Evaluations

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

David Alan Herbst Jr BA & K Rajender Reddy MD

Pages: 527-536

Published online: 01 Mar 2013

Abstractfor Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection | Full Text | References | PDF (434.4 KB)

1366 Views
64 CrossRef citations
0Altmetric

Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?

Meihui Chen, Anmin Liu, Ying Ouyang, Yingjuan Huang, Xiaojuan Chao & Rongbiao Pi

Pages: 537-550

Published online: 05 Mar 2013

Abstractfor Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? | Full Text | References | PDF (573.3 KB)

802 Views
65 CrossRef citations
0Altmetric

Research Article

Article

Related articles

Page: i

Published online: 13 Mar 2013

391 Views
0 CrossRef citations
0Altmetric

Free Access

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

Fernanda Karoline Vieira da Silva Torchelsen et al.

Review Article | Published online: 14 May 2024

Emerging therapies for overactive bladder: preclinical, phase I and phase II studies

Samantha Gibson et al.

Review Article | Published online: 9 May 2024

Frontotemporal dementia: from genetics to therapeutic approaches

Francesca R. Buccellato et al.

Review Article | Published online: 9 May 2024

Open Access

From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?

Swetha Byravan et al.

Review Article | Published online: 9 May 2024

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.22, Iss.4, 2013)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?